magnesium oxide Side Effects
Also known as: Mag-Ox
Analysis of 39,831 adverse event reports submitted to the FDA from 2002 to 2025.
Total Reports
39,831
Death-Related
6,280
15.8% of reports
Hospitalizations
19,832
49.8% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 6,280 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 1,595 |
| PNEUMONIA | 613 |
| SEPSIS | 397 |
| DYSPNOEA | 390 |
| MALIGNANT NEOPLASM PROGRESSION | 386 |
| NAUSEA | 376 |
| INTERSTITIAL LUNG DISEASE | 371 |
| PYREXIA | 362 |
| ANAEMIA | 361 |
| OFF LABEL USE | 347 |
| VOMITING | 318 |
| RESPIRATORY FAILURE | 311 |
| DIARRHOEA | 303 |
| PLATELET COUNT DECREASED | 299 |
| CONDITION AGGRAVATED | 286 |
| DECREASED APPETITE | 282 |
| CONSTIPATION | 275 |
| DISEASE PROGRESSION | 252 |
| ACUTE KIDNEY INJURY | 249 |
| ABDOMINAL PAIN | 218 |
Reactions in Hospitalization Reports
Top reactions in 19,832 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| PNEUMONIA | 1,642 |
| NAUSEA | 1,560 |
| PYREXIA | 1,426 |
| DIARRHOEA | 1,395 |
| DYSPNOEA | 1,298 |
| VOMITING | 1,107 |
| ANAEMIA | 1,092 |
| FATIGUE | 1,048 |
| OFF LABEL USE | 988 |
| DECREASED APPETITE | 897 |
| FALL | 878 |
| ABDOMINAL PAIN | 847 |
| PAIN | 824 |
| MALAISE | 820 |
| HEADACHE | 785 |
| CONSTIPATION | 776 |
| ASTHENIA | 772 |
| ACUTE KIDNEY INJURY | 765 |
| CONDITION AGGRAVATED | 736 |
| DEHYDRATION | 701 |
Nearby — Related Medications
What the FAERS Data Reveals About magnesium oxide Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 39,831 voluntary reports linked to magnesium oxide and its brand equivalents (Mag-Ox), spanning 2002 through 2025. Of those, 6,280 (15.8%) listed death as an outcome and 19,832 (49.8%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 56% were female and 44% male; age distribution skews toward 65-74, with 8,659 reports in that bracket. The single most reported reaction is nausea with 2,795 submissions, followed by diarrhoea and fatigue.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.